Clinical Trials Browser

Phase 2/3 × pegylated granulocyte colony-stimulating factor × 30 days × Clear all

NCT04628767 2026-03-18

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

Renal Pelvis and Ureter Urothelial Carcinoma